- Home
- DTST vs RNTX Comparison
DTST vs RNTX Comparison
Compare DTST & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- RNTX
- Stock Information
- Founded
- DTST 2001
- RNTX 2001
- Country
- DTST United States
- RNTX United States
- Employees
- DTST N/A
- RNTX N/A
- Industry
- DTST EDP Services
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- DTST Technology
- RNTX Health Care
- Exchange
- DTST Nasdaq
- RNTX Nasdaq
- Market Cap
- DTST 32.6M
- RNTX 28.0M
- IPO Year
- DTST N/A
- RNTX N/A
- Fundamental
- Price
- DTST $4.63
- RNTX $1.15
- Analyst Decision
- DTST
- RNTX Hold
- Analyst Count
- DTST 0
- RNTX 1
- Target Price
- DTST N/A
- RNTX N/A
- AVG Volume (30 Days)
- DTST 62.6K
- RNTX 133.3K
- Earning Date
- DTST 11-13-2025
- RNTX 11-13-2025
- Dividend Yield
- DTST N/A
- RNTX N/A
- EPS Growth
- DTST N/A
- RNTX N/A
- EPS
- DTST N/A
- RNTX N/A
- Revenue
- DTST $25,455,742.00
- RNTX N/A
- Revenue This Year
- DTST $12.57
- RNTX N/A
- Revenue Next Year
- DTST $9.29
- RNTX N/A
- P/E Ratio
- DTST N/A
- RNTX N/A
- Revenue Growth
- DTST 0.53
- RNTX N/A
- 52 Week Low
- DTST $2.93
- RNTX $1.04
- 52 Week High
- DTST $5.44
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- DTST 53.20
- RNTX 45.62
- Support Level
- DTST $4.52
- RNTX $1.07
- Resistance Level
- DTST $4.80
- RNTX $1.25
- Average True Range (ATR)
- DTST 0.13
- RNTX 0.14
- MACD
- DTST 0.01
- RNTX -0.01
- Stochastic Oscillator
- DTST 55.26
- RNTX 21.33
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.